Verrica Pharmaceuticals (VRCA) Share-based Compensation (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Share-based Compensation of $897000.0 for Q1 2026, down 12.57% year-over-year from $1.0 million in Q1 2025, and up 30.76% quarter-over-quarter from $686000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Share-based Compensation (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Share-based Compensation history runs 10 years deep, the most recent figure standing at $897000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 12.57% year-over-year to $897000.0; the TTM figure through Mar 2026 stood at $3.2 million (down 47.88% YoY), while the FY2025 annual figure was $3.3 million, down 53.69% from the prior year.
- Share-based Compensation for Q1 2026 stood at $897000.0, up from $686000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $9.7 million in Q3 2023, with the low at $686000.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $1.2 million (2022), against an average of $1.8 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation soared 583.86% in 2023, then plunged 78.18% in 2024.
- Verrica Pharmaceuticals' Share-based Compensation stood at $1.2 million in 2022, then surged by 77.2% to $2.1 million in 2023, then slumped by 63.57% to $756000.0 in 2024, then fell by 9.26% to $686000.0 in 2025, then soared by 30.76% to $897000.0 in 2026.
- Business Quant data shows VRCA's Share-based Compensation at $897000.0 in Q1 2026, $686000.0 in Q4 2025, and $718000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | - |
| 10 | Verrica Pharmaceuticals | 106.31 Mn | 95.11 Mn | - | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Mn |
| Jun 30, 2026 | 1.21 Mn |
| Mar 31, 2026 | 897,000.00 |
| Mar 31, 2026 | 897,000.00 |
| Dec 31, 2025 | 686,000.00 |
| Dec 31, 2025 | 686,000.00 |
| Sep 30, 2025 | 718,000.00 |
| Sep 30, 2025 | 718,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Mar 31, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | 756,000.00 |
| Dec 31, 2024 | 756,000.00 |
| Sep 30, 2024 | 2.11 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |